News | November 10, 2021
Moderna seeks approval from EMA for its Covid-19 vaccine for children between 6-11 years
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
Filing marks first protein-based vaccine submitted to MHRA for authorization
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
This strategic collaboration will enable continued innovation in cancer care
The division is expected to grow to over a 100-member strong team by 2022
Subscribe To Our Newsletter & Stay Updated
